世界のベバシズマブバイオシミラー市場(~2025):市場機会・売上・価格・臨床試験インサイト

◆英語タイトル:Bevacizumab Biosimilar Market Opportunity , Sales, Price and Clinical Trials Insight 2025
◆商品コード:KUIK21FB005
◆発行会社(リサーチ会社):Kuick Research
◆発行日:2020年12月
◆ページ数:120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single userUSD2,000 ⇒換算¥228,000見積依頼/購入/質問フォーム
Multi UserUSD3,600 ⇒換算¥410,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuick Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Kuick Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本市場調査レポートでは、世界のベバシズマブバイオシミラー市場について調査・分析を行い、市場概要、商業的利用可能性、市場分析、臨床試験動向、フェース別臨床試験動向、将来見通し、競争状況などを掲載しています。
・市場概要
・商業的利用可能性
・市場分析
・臨床試験動向
・フェース別臨床試験動向
・将来見通し
・競争状況
【レポートの概要】

“Bevacizumab Biosimilar Market Opportunity, Sales, Price and Clinical Trials Insight 2025″ Report Highlights:

Bevacizumab Market Opportunity: > USD 12 Billion by 2025
Bevacizumab Biosimilar in Clinical Trials: > 25 Biosimilars
Bevacizumab Biosimilar Available in Market: >8 Biosimilars
Bevacizumab Market Spread: US and Europe Share > 60%
Bevacizumab Branded v/s Biosimilar Insight
Avastin and Bevacizumab Biosimilar Price, Sales and Dosage Insight
Bevacizumab Patent Insight by Indication and Year

Bevacizumab is among the cusp of getting recognized as one of the most prominent drugs for the treatment of multiple types of cancer. Being an innovative approach of immunotherapy capable of neutralizing vascular endothelial growth factor, it got its fast-end approval as a first anti-angiogenic therapy by the regulatory bodies for the benefit of millions of cancer patients. The parent bio-pharmaceutical company of the drug is F. Hoffmann-La Roche AG and in the year 2004, the drug got recognized as one of the promising immunotherapy drugs as a first-line therapy when combined with intravenous 5-fluorouracil-based chemotherapy for the treatment of the patients suffering from metastatic colorectal cancer. Application wise, the drug has extended its wings for the treatment of colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, and ovarian cancer. Such huge segmentation of the global bevacizumab biosimilar drug tends to deliver the large percentage it is contributing to the global cancer biosimilar market.

The emergence of bevacizumab biosimilar drug for the cancer patients have burnt all the issues that were recorded in the past few years i.e. comparison of the biosimilar drugs with the reference drugs. The 20 years of experience of bevacizumab biosimilar drug in the market has achieved high comfort level and rise in overall cancer therapeutics market that was not imagined by the researchers and the patients. The drug market is witnessed to deliver high growing healthcare benefits as the opportunities related with the cancer treatment is apparently more when compared with the treatment expenses of other biological cancer treatments.

The global market of the drug has created a jinxed for the biosimilar market, thus making the researchers and the patients lean towards this mode of treatment as one of the most prominent types. In addition to this, the overall drug market in a very short period of time has come up with high valued and worthy outcome to the parent company and it is seeking towards more robust performance with novel trends in the upcoming years. The market in a very short period of time has been successful in establishing a primary goal for over-shadowing the expensive nature of the cancer treatment towards a novel approach that is cheap, affordable and as beneficial as the reference product.

The analysis of the bevacizumab biosimilar drug performance has landed high market expectations and a classification of the drug market that is 100% accurate in terms of mechanism of action, chemical properties and many more. The association of the market with strong and prominent research team of the parent company is all focused on making the drug as a solo treatment regimen with high quality in combination with other therapies so that all the current challenges could be over-come in short period of time. In addition, it is estimated that the biosimilar drug market of bevacizumab has been able to introduce a unique revolution in the entire biosimilar market, thus resulting in creating a landscape that is successful and central component to trillion dollars cancer therapeutics market.

【レポートの目次】

Bevacizumab – Current Market Overview

Bevacizumab – Reimbursement Scenario

Bevacizumab – Commercial Availability
3.1 Dosage, Patent and Price Analysis – Branded v/s Biosimilar
3.1.1 Avastin
3.1.2 Mvasi
3.1.3 Zirabev
3.1.4 Aybintio
3.2 Avastin – Sales Analysis

Bevacizumab Biosimilar Market Analysis
4.1 Current Market Scenario
4.2 Market Opportunities and Forecast

Global Bevacizumab Biosimilar Ongoing Clinical Trials Outlook
5.1 Country
5.2 Indication
5.3 Patient Segment
5.4 Organization

Global Bevacizumab Biosimilar Clinical Insight By Phase
6.1 Unknown
6.2 Research
6.3 Preclinical
6.4 Clinical
6.5 Phase-I
6.6 Phase-II
6.7 Phase-II/III
6.8 Phase-III
6.9 Preregistration
6.10 Registered

Marketed Bevacizumab Branded and Biosimilar Drug Clinical Insight
7.1 Avastin
7.2 Bevacizumab Biosimilar – KRABEVA
7.3 Bevacizumab Biosimilar – BYVASDA
7.4 Bevacizumab Biosimilar – Bevax
7.5 Bevacizumab Biosimilar – ZIRABEV
7.6 Bevacizumab Biosimilar – Mvasi
7.7 Bevacizumab Biosimilar – Bryxta
7.8 Bevacizumab Biosimilar Bevatas
7.9 Bevacizumab Biosimilar – Cizumab
7.10 Bevacizumab Biosimilar – Versavo
7.11 Bevacizumab Biosimilar – Lumiere

Bevacizumab Biosimilar Market – Future Outlook

Competitive Landscape
9.1 Amgen
9.2 AryoGen Pharmed
9.3 Biothera
9.4 Boehringer Ingelheim
9.5 Centus Biotherapeutics
9.6 Henlius Biotech
9.7 Innovent Biologics
9.8 Mylan
9.9 mAbxience
9.10 Outlook Therapeutics
9.11 Pfizer
9.12 Prestige Biopharma
9.13 Roche
9.14 Samsung Bio
9.15 TOT Biopharm



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界のベバシズマブバイオシミラー市場(~2025):市場機会・売上・価格・臨床試験インサイト]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆